Clinical trial
Lenalidomide and Cyclophosphamide in Treating Patients With Previously Treated Hormone-Refractory Prostate Cancer
NCT01093183
Study timeline
Study start (actual)2010-03-04Date precision: day
Registry last updated2023-09-13
Observed by CureCurrent2026-10-07
Recorded dates are source observations, not predictions. Missing milestones are not estimated.
Conditions
Adenocarcinoma of the Prostateunresolved
Hormone-resistant Prostate Cancerunresolved
Recurrent Prostate Cancerunresolved
Interventions
lenalidomideDRUG · verified · RxNorm: lenalidomide
cyclophosphamideDRUG · verified · RxNorm: cyclophosphamide
Sponsors & collaborators
University of Nebraskalead sponsor
National Cancer Institute (NCI)collaborator
Mapped research locations
Registry source
Open the source record to verify current eligibility, contacts, locations and registry updates.
Open NCT01093183 on ClinicalTrials.gov ↗Registry-derived research relationships: ClinicalTrials.gov. Raw condition and intervention labels remain distinct from canonical MONDO/RxNorm entities unless separately normalized.